Steroid before infliximab for inflammatory bowel disease
Treatments studied
Part of Digestive system clinical trials.
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 80 years old.
- You have a confirmed diagnosis of Crohn's disease or ulcerative colitis (inflammatory bowel disease), and your disease is moderate to severe.
- You are not currently taking immunosuppressant drugs like azathioprine, and you won't start them for the next two months.
- If you take steroid pills, you are on a low dose (10 or fewer per day) and plan to taper off completely within two months.
- You are about to receive your first dose of infliximab (a biologic drug) within two weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
Hear when a new Inflammatory Bowel Disease (IBD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.